For the committee, some of the reasons it used to reject adding Pompe disease to Australia’s newborn bloodspot screening programs are perversely the same as those it invoked to support the addition of Hurler (MPS I) and Hunter (MPS II) syndromes.
Decision-making at its nadir, exposing the cruelty of incoherence
September 16, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Podcast - Series 5, Ep.25
July 24, 2026 - - Podcast -
Finalists named for the 2026 Patient's Choice awards
July 24, 2026 - - Latest News -
Australian company moving headquarters to US and restructuring workforce
July 24, 2026 - - Latest News -
The 'end of days' language is just a farcical attempt to shut down discussion
July 24, 2026 - - Latest News -
How national HPV vaccination programs are changing the story of cervical cancer
July 23, 2026 - - Latest News -
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - - Latest News -
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
July 23, 2026 - - Latest News

